Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Condition: Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Intervention: Drug: SC291 Sponsor: Sana Biotechnology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Research | Study